Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Albrecht

Showing results (211-220 of 245) with videos related to

Pageof 25
Sort By:
Hepatology (Baltimore, Md.)|April 14, 2011
Racial differences in hepatitis C treatment eligibilityMichael T Melia, Andrew J Muir, Jonathan McCone, et al.
Pain|February 20, 2010
Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent painBaoXi Gao, Markus Hierl, Kristie Clarkin, et al.
Journal of Medicinal Chemistry|January 27, 2016
Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor ActivityAlessandro A Boezio, Katrina W Copeland, Karen Rex, et al.
Journal of Medicinal Chemistry|August 6, 2008
Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonistsYuan Cheng, Brian K Albrecht, James Brown, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2015
Development of methyl isoxazoleazepines as inhibitors of BETMichael C Hewitt, Yves Leblanc, Victor S Gehling, et al.
Journal of Viral Hepatitis|April 14, 2012
Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment responseP J Clark, A J Thompson, M Zhu, et al.
Journal of Viral Hepatitis|July 2, 2013
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirinM P Manns, P J Pockros, G Norkrans, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 15, 2013
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trialsMichael P Manns, Jonathan McCone, Mitchell N Davis, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2007
Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitorsBrian L Hodous, Stephanie D Geuns-Meyer, Paul E Hughes, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET BromodomainsAlexander M Taylor, Rishi G Vaswani, Victor S Gehling, et al.
Pageof 25

Showing results (211-220 of 245) with videos related to

Sort By:
Pageof 25
Hepatology (Baltimore, Md.)|April 14, 2011
Racial differences in hepatitis C treatment eligibilityMichael T Melia, Andrew J Muir, Jonathan McCone, et al.
Pain|February 20, 2010
Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent painBaoXi Gao, Markus Hierl, Kristie Clarkin, et al.
Journal of Medicinal Chemistry|January 27, 2016
Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor ActivityAlessandro A Boezio, Katrina W Copeland, Karen Rex, et al.
Journal of Medicinal Chemistry|August 6, 2008
Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonistsYuan Cheng, Brian K Albrecht, James Brown, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2015
Development of methyl isoxazoleazepines as inhibitors of BETMichael C Hewitt, Yves Leblanc, Victor S Gehling, et al.
Journal of Viral Hepatitis|April 14, 2012
Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment responseP J Clark, A J Thompson, M Zhu, et al.
Journal of Viral Hepatitis|July 2, 2013
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirinM P Manns, P J Pockros, G Norkrans, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 15, 2013
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trialsMichael P Manns, Jonathan McCone, Mitchell N Davis, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2007
Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitorsBrian L Hodous, Stephanie D Geuns-Meyer, Paul E Hughes, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET BromodomainsAlexander M Taylor, Rishi G Vaswani, Victor S Gehling, et al.
Pageof 25